SCHEMBL771638

SCHEMBL771638

O=C(CCCC(=O)N1CCCC2CCCCC21)NC[C@H](O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ASAH1 Q13510 1/20 0.50
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.42
HSD11B1 P28845 3/20 0.42
DPP4 P27487 1/20 0.41
BCAT2 O15382 1/20 0.40
BCHE P06276 3/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B1 P14061 1/20 0.39
MEN1 O00255 1/20 0.39
ACE P12821 2/20 0.39
ACE2 Q9BYF1 1/20 0.39
DUT P33316 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15386649 1.00 ASAH1 (0.50) ASAH1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL771117 0.91 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1DPP4
SCHEMBL770941 0.88 TAAR1 (0.47) ASAH1NPC1RAB9ASMN1; SMN2HSD11B1
SCHEMBL770231 0.87 MEN1 (0.53) NPC1RAB9ASMN1; SMN2KDM4EHSD11B1
SCHEMBL771606 0.86 DPP4 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1DPP4
SCHEMBL802601 0.84 ALDH1A1 (0.49) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL770291 0.82 GAA (0.56) NPC1RAB9ASMN1; SMN2LMNAHSD11B1
SCHEMBL772523 0.82 PRCP (0.50) NPC1RAB9ASMN1; SMN2LMNADPP4
SCHEMBL771118 0.82 PRCP (0.50) NPC1RAB9ASMN1; SMN2LMNADPP4
SCHEMBL771811 0.81 ALDH1A1 (0.53) ASAH1NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ASAH1 143/4885NPC1 97/4885RAB9A 2187/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ASAH1 145/4885NPC1 104/4885RAB9A 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.